Navigation Links
Huntsman Cancer Institute Uses Linguamatics I2E to Automatically Extract Insights from Clinical Pathology Documents
Date:11/18/2013

CAMBRIDGE, England and BOSTON, Nov. 18, 2013 /PRNewswire/ -- Linguamatics, the leader in natural language processing-based text mining and analytics, today announced that Huntsman Cancer Institute (HCI) at the University of Utah has deployed its natural language processing (NLP) based I2E software platform to transform the immense stores of unstructured text in electronic health records (EHRs) into actionable information to drive improvements in cancer research, treatments and outcomes.

HCI is using Linguamatics I2E with its in-house clinical informatics infrastructure to extract discrete data from the unstructured text contained in surgical, pathology, radiology, and clinical notes related to hematology oncology disease areas such as Leukemia and Lymphoma. The resulting data is loaded into an integrated biobanking, clinical research, and genomic annotation platform. This enables HCI's clinicians and principal investigators to harness the richest possible set of data for research into patient outcomes, comparative effectiveness, and genetic drivers of disease. Analysis at this scale can find information that would often be missed when reading documents one at a time. In addition HCI has a better range and quality of data to support clinical trial matching and increase numbers of patients on trials.

"Healthcare organizations face a major challenge to identify, capture and leverage valuable knowledge buried within vast stores of complex, unstructured patient data, and to do it in a reproducible and scalable way," commented Phil Hastings, Snr Vice President, Sales and Marketing, at Linguamatics. "When abstracting detailed patient data, a clinical research assistant may look at multiple documents and spend several hours per patient to get all their radiology, pathology and surgical data curated. To perform this work at a meaningful scale is both laborious and expensive."

"I2E is a uniquely agile and scalable NLP platform, which empowers organizations to successfully address the data abstraction challenge," continued Dr Hastings. "We are pleased to be working with Huntsman Cancer Institute in their drive to streamline and extend their healthcare analytics efforts and positively impact research processes and patient outcomes."

ABOUT LINGUAMATICS
Linguamatics is the world leader in innovative health science focused natural language processing (NLP) solutions for high-value knowledge discovery, information extraction and decision support.

Linguamatics I2E text mining platform is used by leading hospitals, the U.S. Food and Drug Administration, premier academic institutions and nine of the top ten pharmaceuticals to transform unstructured and semi structured data into improved patient care and insights. I2E is able to mine any text-based resources, such as electronic health records, pathology and radiology reports, initial assessments, discharge summaries and ICU notes to support knowledge extraction for use in data warehouses, biobanks, disease registries, predictive models and healthcare analytics. I2E allows medical information experts who are not developers to quickly build and modify queries that extract information which is critical to supporting Meaningful Use, comparative effectiveness and adherence to care pathways.

Linguamatics is committed to excellence in healthcare informatics and is a corporate member of AMIA, HIMSS and the MLA. The company operates globally, with headquarters in Cambridge, UK, and a U.S. office near Boston, MA. For more information, visit www.linguamatics.com/healthcare or www.whatistextmining.com.

Contact:

Danielle Guinebertiere
Office: +1 978 254 5587
Email

Read more news from Linguamatics.

 


'/>"/>
SOURCE Linguamatics
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020
2. Virobays Spectrum-Selective Cathepsin Inhibitor Shows Efficacy in Bone Cancer Model
3. Biocept and Academic Collaborators to Present Posters at San Antonio Breast Cancer Symposium on Circulating Tumor Cells (CTCs)
4. NKTR-102 Demonstrates Synergistic Anti-Tumor Activity in Combination with Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer
5. Members of Congress, Cancer Experts Address Impact of Genetic Testing on Cancer
6. Masaryk Memorial Cancer Institute Reduces Losses and Administrative Overhead With Ekahau RTLS
7. BBVA Foundation Unites the Efforts of Massachusetts General Hospital and Barcelonas Vall dHebron Hospital in Biomarker Research for Personalized Cancer Therapies
8. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
9. New research points to benefits of innovative cobas® HPV test for primary screening as Englands cervical cancer screening programme includes the test in current HPV "triage" rollout
10. A New Type of Dendritic Cell-Based Cancer Vaccine has Received Approval for Clinical Tests and at the Same Time Secures Substantial Financing
11. US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... 16, 2017   Biostage, Inc. (Nasdaq: ... company developing bioengineered organ implants to treat cancers and ... announced today the closing on February 15, 2017 of ... common stock and warrants to purchase 20,000,000 shares of ... The offering was priced at $0.40 per share of ...
(Date:2/16/2017)...  Dermata Therapeutics, LLC, a biotechnology company developing ... of dermatological diseases, today announced it has completed ... into a $5 million credit facility with Silicon ... capital for general corporate purposes to further Dermata,s ... of serious diseases treated by dermatologists.   ...
(Date:2/16/2017)...  Windtree Therapeutics, Inc. (Nasdaq: WINT ... KL4 surfactant therapies for respiratory diseases, announced today ... that aerosolized KL4 surfactant reduced lung inflammation and ... model. The Company believes that these preclinical data ... supports the role of KL4 surfactant as a ...
(Date:2/16/2017)... ... February 16, 2017 , ... ... industry leading Biochemistry Services specifically targeting the rapidly growing needs of the ... the biochemical and biosimilar characterization , product-related impurity characterization, aggregation ...
Breaking Biology Technology:
(Date:1/19/2017)... January 19, 2017 According to a new report published ... 2014 - 2022," the global biometric sensor market is expected to garner $1.5 ... In 2015, Asia-Pacific dominated the global market and contributed ... Continue Reading ... ...
(Date:1/18/2017)... -- In vitro diagnostic (IVD) companies were very active in ... Kalorama Information expects that trend to continue – though ... uncertainty in reimbursement and healthcare reform in ... acquisitions landscape. Instead of looking to buy technology, the ... of their home country and also to increase their ...
(Date:1/13/2017)... , Jan. 13, 2017 Sandata ... solutions for the homecare industry, including Electronic Visit ... industry expert, Justin Jugs, as Senior Vice President ... than 15 years of homecare experience to Sandata, ... developing strategic plans to align Sandata,s suite of ...
Breaking Biology News(10 mins):